Reimbursement Status and Recommendations Related to Orphan Drugs in European Countries

Reimbursement Status and Recommendations Related to Orphan Drugs in European Countries

Objective: To review the reimbursement recommendations issued by selected European health technology assessment agencies for orphan drugs and the reimbursement status of these drugs; to assess the relationship between the type of recommendation and reimbursement status.Methods: The list of orphan dr...

Full description

Bibliographic Details
Main Authors:	Ewa Stawowczyk, Krzysztof Piotr Malinowski, Paweł Kawalec, Rafał Bobiński, Jacek Siwiec, Dimitra Panteli, Helene Eckhardt, Steven Simoens, Antònia Agusti, Marc Dooms, Andrzej Pilc
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2019-11-01
Series:	Frontiers in Pharmacology
Subjects:	health technology assessment drug policy rare disease reimbursement orphan
Online Access:	https://www.frontiersin.org/article/10.3389/fphar.2019.01279/full

Similar Items

Reimbursement of Orphan Drugs in Europe in Relation to the Type of Authorization by the European Medicines Agency and the Decision Making Based on Health Technology Assessment
by: Krzysztof Piotr Malinowski, et al.
Published: (2018-11-01)

A systematic review of moral reasons on orphan drug reimbursement
by: Bettina M. Zimmermann, et al.
Published: (2021-06-01)

Clinical aspects of reimbursement policies for orphan drugs in Central and Eastern European countries
by: Szczepan Jakubowski, et al.
Published: (2024-03-01)

Reimbursement decisions for medical services in Austria: an analysis of influencing factors for the hospital individual services catalogue between 2008 and 2020
by: Gregor Goetz, et al.
Published: (2022-02-01)

How Can We Optimize the Value Assessment and Appraisal of Orphan Drugs for Reimbursement Purposes? A Qualitative Interview Study Across European Countries
by: Alessandra Blonda, et al.
Published: (2022-07-01)

Health technology assessment and reimbursement policy for oncology orphan drugs in Central and Eastern Europe
by: Krzysztof Piotr Malinowski, et al.
Published: (2020-10-01)

Impact of the therapeutic positioning report in the P&R process in Spain: analysis of orphan drugs approved by the European Commission and reimbursed in Spain from 2003 to 2019
by: Xavier Badia, et al.
Published: (2020-08-01)

Are payers treating orphan drugs differently?
by: Joshua P. Cohen, et al.
Published: (2014-01-01)

Are supplemental appraisal/reimbursement processes needed for rare disease treatments? An international comparison of country approaches
by: Elena Nicod, et al.
Published: (2020-07-01)

The European challenges of funding orphan medicinal products
by: Márta Szegedi, et al.
Published: (2018-11-01)

Benefit Assessment and Reimbursement of Digital Health Applications: Concepts for Setting Up a New System for Public Coverage
by: Hendrikje Lantzsch, et al.
Published: (2022-04-01)

Comparing access to orphan medicinal products in Europe
by: Bernarda Zamora, et al.
Published: (2019-05-01)

Factors associated with positive and negative recommendations for cancer and non-cancer drugs for rare diseases in Canada
by: Fernanda Naomi Inagaki Nagase, et al.
Published: (2019-06-01)

Pricing of orphan drugs in oncology and rare diseases
by: Mark Nuijten, et al.
Published: (2020-01-01)

Orphan Medicine Incentives: How to Address the Unmet Needs of Rare Disease Patients by Optimizing the European Orphan Medicinal Product Landscape Guiding Principles and Policy Proposals by the European Expert Group for Orphan Drug Incentives (OD Expert Group)
by: Annemieke Aartsma-Rus, et al.
Published: (2021-12-01)

Off-label use of orphan medicinal products: a Belgian qualitative study
by: Marc Dooms, et al.
Published: (2016-10-01)

A Review of Rare Disease Policies and Orphan Drug Reimbursement Systems in 12 Eurasian Countries
by: Marcin Czech, et al.
Published: (2020-01-01)

Cost-Effectiveness Analysis of 1-Year Treatment with Golimumab/Standard Care and Standard Care Alone for Ulcerative Colitis in Poland.
by: Ewa Stawowczyk, et al.
Published: (2016-01-01)

Comparative Analysis of Legislative Requirements About Patients' Access to Biotechnological Drugs for Rare Diseases in Central and Eastern European Countries
by: Maria Kamusheva, et al.
Published: (2018-07-01)

Multi-criteria decision analysis for assessment and appraisal of orphan drugs
by: Georgi Iskrov, et al.
Published: (2016-09-01)

ODs with a positive TPR conclusion, not subject to a conditional approval, and approved without requering a pass would be more likely to be reimbursed in Spain
by: José Luis Poveda, et al.
Published: (2023-01-01)

Strategic discussion on funding and access to therapies targeting rare diseases in Spain: an expert consensus paper
by: N. Zozaya, et al.
Published: (2023-02-01)

Pricing and Reimbursement of Biosimilars in Central and Eastern European Countries
by: Paweł Kawalec, et al.
Published: (2017-06-01)

Orphan devices: yesterday is history; tomorrow is mystery: towards a European orphan device directive?
by: Marc M Dooms
Published: (2016-03-01)

Analysis of patient access to orphan drugs in Turkey
by: Güvenç Koçkaya, et al.
Published: (2021-02-01)

Orphan Drugs, Compounded Medication and Pharmaceutical Commons
by: Kim Hendrickx, et al.
Published: (2021-09-01)

Implementation of innovative medical technologies in German inpatient care: patterns of utilization and evidence development
by: Marie Dreger, et al.
Published: (2021-10-01)

Correction to: Implementation of innovative medical technologies in German inpatient care: patterns of utilization and evidence development
by: Marie Dreger, et al.
Published: (2022-01-01)

Orphan drugs and rare diseases /
by: Pryde, David C., editor, et al.
Published: (2014)

Reimbursement process of medicinal products in Poland and in the world
by: Aneta Katarzyna Mela
Published: (2020-09-01)

Practice of the Qualification and Recognition for Orphan Drugs in the World and its Inspiration
by: ZHU Xiaohong, et al.
Published: (2022-07-01)

An analysis of orphan medicine expenditure in Europe: is it sustainable?
by: Jorge Mestre-Ferrandiz, et al.
Published: (2019-12-01)

Trends in orphan medicinal products approvals in the European Union between 2010–2022
by: Luísa Bouwman, et al.
Published: (2024-02-01)

Engaging the Canadian public on reimbursement decision-making for drugs for rare diseases: a national online survey
by: Julie Polisena, et al.
Published: (2017-05-01)

Pricing Zolgensma – the world’s most expensive drug
by: Mark Nuijten
Published: (2022-12-01)

Cross-national comparative study of orphan drug policies in Saudi Arabia, the United States, and the European Union
by: Bander Balkhi, et al.
Published: (2023-09-01)

Patient access to orphan drugs in France
by: Marion Bourdoncle, et al.
Published: (2019-02-01)

Utilization of innovative medical technologies in German inpatient care: does evidence matter?
by: Helene Eckhardt, et al.
Published: (2023-10-01)

The work, goals, challenges, achievements, and recommendations of orphan medicinal product organizations in India: an interview-based study
by: Mohua Chakraborty Choudhury, et al.
Published: (2019-11-01)

Features of intellectual property protection mechanisms on the example of orphan drugs circulation
by: D. S. Yurochkin, et al.
Published: (2022-01-01)